IGF‐1 as screening tool for acromegaly and adult‐onset growth hormone deficiency in the Netherlands

Abstract

AbstractObjectiveInsulin‐like growth factor 1 (IGF‐1) measurements play a central role in the diagnosis and follow‐up of acromegaly and growth hormone deficiency. However, improving health care outcomes for these patients involves an intricate process of laboratory diagnostics and skilled health care professionals. The integrated effects of IGF‐1 reports on diagnosis and treatment decisions are yet unknown.Design, Patients and MeasurementsExtended quality assessment, distributing the description of five (real) patient cases with accompanying blood samples. Patients suspected or during follow up for acromegaly or adult onset of growth hormone deficiency were included. Laboratory specialists and endocrinologists in the same centre were asked to interpret their centre‐specific IGF‐1 results by using a laboratory and medical questionnaire. This way, insight could be obtained into the combined effects of different assays, assay harmonisation, reference value sets, and individual physician interpretation in relation to guidelines, thus reviewing the entire diagnostic and management process.ResultsLimited variation (CV 13.8 ± 2.8) was found in IGF‐1 concentrations despite different use of the harmonization sample and factor among laboratories. This interlaboratory variation increased upon conversion to SD scores (CV 15.7 ± 40.7) as a consequence of the use of different reference value sets. Furthermore, there was a lack of adherence to international guidelines among endocrinologists.ConclusionsHighly variable diagnostic and treatment outcomes in acromegaly and AGHD in the Netherlands can be attributed to increased variability of IGF‐1 upon conversion to SD scores and low adherence to clinical guidelines.